NurExone Biologic Past Earnings Performance
Past criteria checks 0/6
NurExone Biologic's earnings have been declining at an average annual rate of -9%, while the Pharmaceuticals industry saw earnings growing at 43.4% annually.
Key information
-9.0%
Earnings growth rate
13.9%
EPS growth rate
Pharmaceuticals Industry Growth | 23.1% |
Revenue growth rate | n/a |
Return on equity | -160.8% |
Net Margin | n/a |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Revenue & Expenses Breakdown
How NurExone Biologic makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 0 | -4 | 3 | 0 |
31 Mar 24 | 0 | -4 | 2 | 0 |
31 Dec 23 | 0 | -4 | 2 | 0 |
30 Sep 23 | 0 | -4 | 2 | 0 |
30 Jun 23 | 0 | -4 | 2 | 0 |
31 Mar 23 | 0 | -7 | 3 | 0 |
31 Dec 22 | 0 | -8 | 4 | 0 |
30 Sep 22 | 0 | -8 | 4 | 0 |
30 Jun 22 | 0 | -7 | 4 | 0 |
31 Mar 22 | 0 | -4 | 3 | 0 |
Quality Earnings: NRX is currently unprofitable.
Growing Profit Margin: NRX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if NRX's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare NRX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NRX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-51.1%).
Return on Equity
High ROE: NRX has a negative Return on Equity (-160.82%), as it is currently unprofitable.